{"id":383422,"date":"2020-11-17T16:08:31","date_gmt":"2020-11-17T21:08:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383422"},"modified":"2020-11-17T16:08:31","modified_gmt":"2020-11-17T21:08:31","slug":"dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/","title":{"rendered":"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">EMERYVILLE, Calif.<\/span>, <span class=\"xn-chron\">Nov. 17, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2985225-1&amp;h=1617518427&amp;u=http%3A%2F%2Fwww.dynavax.com%2F&amp;a=Dynavax+Technologies+Corporation\" rel=\"nofollow noopener noreferrer\">Dynavax Technologies Corporation<\/a> (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2985225-1&amp;h=2247857955&amp;u=https%3A%2F%2Fwww.dynavax.com%2Fabout%2F%23management&amp;a=Ryan+Spencer\" rel=\"nofollow noopener noreferrer\"><span class=\"xn-person\">Ryan Spencer<\/span><\/a>, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on <span class=\"xn-chron\">Thursday, December 3<\/span>, at 10:05 a. m. E.T.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg\" title=\"(PRNewsfoto\/Dynavax Technologies)\" alt=\"(PRNewsfoto\/Dynavax Technologies)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The live audio webcast may be accessed through the &#8220;Events &amp; Presentations&#8221; page on the &#8220;Investors&#8221; section of the Company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2985225-1&amp;h=2901820090&amp;u=http%3A%2F%2Fwww.dynavax.com%2F&amp;a=www.dynavax.com\" rel=\"nofollow noopener noreferrer\">www.dynavax.com<\/a>. A replay of the webcast will be available for 30 days following the live event.<\/p>\n<p>\n        <b>About Dynavax<br \/><\/b>Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company&#8217;s first commercial product, HEPLISAV-B\u00ae [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships.\u00a0Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2985225-1&amp;h=2991087346&amp;u=https%3A%2F%2Fwww.dynavax.com%2F&amp;a=www.dynavax.com\" rel=\"nofollow noopener noreferrer\">www.dynavax.com<\/a> and follow the company on <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2985225-1&amp;h=2068246139&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fdynavax-technologies%2F&amp;a=LinkedIn\" rel=\"nofollow noopener noreferrer\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Nicole Arndt<\/span>, Senior Manager, Investor Relations <br \/><a target=\"_blank\" href=\"mailto:narndt@dynavax.com\" rel=\"nofollow noopener noreferrer\">narndt@dynavax.com<\/a>\u00a0<br \/>510-665-7264<\/p>\n<p>\n        <span class=\"xn-person\">Derek Cole<\/span>, President<br \/>Investor Relations Advisory Solutions <br \/><a target=\"_blank\" href=\"mailto:derek.cole@IRadvisory.com\" rel=\"nofollow noopener noreferrer\">derek.cole@IRadvisory.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF95260&amp;sd=2020-11-17\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference-301175311.html\">http:\/\/www.prnewswire.com\/news-releases\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference-301175311.html<\/a><\/p>\n<p>SOURCE  Dynavax Technologies<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF95260&amp;Transmission_Id=202011171605PR_NEWS_USPR_____SF95260&amp;DateId=20201117\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire EMERYVILLE, Calif., Nov. 17, 2020 \/PRNewswire\/ &#8212;\u00a0Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T. The live audio webcast may be accessed through the &#8220;Events &amp; Presentations&#8221; page on the &#8220;Investors&#8221; section of the Company&#8217;s website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event. About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company&#8217;s first commercial product, HEPLISAV-B\u00ae [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383422","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire EMERYVILLE, Calif., Nov. 17, 2020 \/PRNewswire\/ &#8212;\u00a0Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T. The live audio webcast may be accessed through the &#8220;Events &amp; Presentations&#8221; page on the &#8220;Investors&#8221; section of the Company&#8217;s website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event. About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company&#8217;s first commercial product, HEPLISAV-B\u00ae [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved &hellip; Continue reading &quot;Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-17T21:08:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference\",\"datePublished\":\"2020-11-17T21:08:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/\"},\"wordCount\":236,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1273133\\\/Dynavax_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/\",\"name\":\"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1273133\\\/Dynavax_Logo.jpg\",\"datePublished\":\"2020-11-17T21:08:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1273133\\\/Dynavax_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1273133\\\/Dynavax_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference - Market Newsdesk","og_description":"PR Newswire EMERYVILLE, Calif., Nov. 17, 2020 \/PRNewswire\/ &#8212;\u00a0Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T. The live audio webcast may be accessed through the &#8220;Events &amp; Presentations&#8221; page on the &#8220;Investors&#8221; section of the Company&#8217;s website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event. About DynavaxDynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company&#8217;s first commercial product, HEPLISAV-B\u00ae [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved &hellip; Continue reading \"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-17T21:08:31+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference","datePublished":"2020-11-17T21:08:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/"},"wordCount":236,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/","name":"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg","datePublished":"2020-11-17T21:08:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1273133\/Dynavax_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383422"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383422\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}